TipRanks
Advertisement
Advertisement

SLXN Stock Latest News

After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)
TipRanks NewswireAfter Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)
27d ago
MRK
MRNA
Silexion Therapeutics Receives Nasdaq Delisting Notice, Plans Appeal
PremiumCompany Announcements
Silexion Therapeutics Receives Nasdaq Delisting Notice, Plans Appeal
1M ago
8K
SLXN
Silexion Therapeutics prices $2.5M public offering at $0.65 per share
PremiumThe Fly
Silexion Therapeutics prices $2.5M public offering at $0.65 per share
1M ago
SLXN
Silexion Therapeutics Executes Reverse Share Split Amid Strain
PremiumCompany Announcements
Silexion Therapeutics Executes Reverse Share Split Amid Strain
1M ago
8K
SLXN
Silexion Therapeutics Closes Public Offering and Strengthens Equity
PremiumCompany Announcements
Silexion Therapeutics Closes Public Offering and Strengthens Equity
1M ago
8K
SLXN
Immunotherapy’s Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN)
PremiumTipRanks NewswireImmunotherapy’s Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN)
1M ago
MRK
SLXN
Silexion Updates SIL204 Clinical and Regulatory Roadmap
Premium
Company Announcements
Silexion Updates SIL204 Clinical and Regulatory Roadmap
1M ago
8K
SLXN
Silexion Therapeutics files to sell ordinary shares, warrants, no amount given
Premium
The Fly
Silexion Therapeutics files to sell ordinary shares, warrants, no amount given
2M ago
SLXN
Silexion unveils key SIL204 KRAS preclinical findings
PremiumCompany Announcements
Silexion unveils key SIL204 KRAS preclinical findings
2M ago
8K
SLXN
Silexion Therapeutics Restores Nasdaq Audit Committee Compliance
PremiumCompany Announcements
Silexion Therapeutics Restores Nasdaq Audit Committee Compliance
2M ago
8K
SLXN
Silexion Therapeutics Announces Board Member Resignation
PremiumCompany Announcements
Silexion Therapeutics Announces Board Member Resignation
2M ago
8K
SLXN
Silexion Begins Phase 2/3 Trial in Pancreatic Cancer
PremiumCompany Announcements
Silexion Begins Phase 2/3 Trial in Pancreatic Cancer
2M ago
8K
SLXN
Silexion Therapeutics downgraded at Maxim on delisting and dilution risk
PremiumThe FlySilexion Therapeutics downgraded at Maxim on delisting and dilution risk
2M ago
SLXN
Silexion Therapeutics downgraded to Hold from Buy at Maxim
Premium
The Fly
Silexion Therapeutics downgraded to Hold from Buy at Maxim
2M ago
SLXN
Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)
Premium
TipRanks Newswire
Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)
2M ago
SLXN
Silexion Therapeutics initiates SIL204 trial
PremiumThe Fly
Silexion Therapeutics initiates SIL204 trial
2M ago
SLXN
Silexion Therapeutics Shareholders Approve Capital Structure Changes
PremiumCompany Announcements
Silexion Therapeutics Shareholders Approve Capital Structure Changes
2M ago
8K
SLXN
Silexion Therapeutics files to sell 859,609 ordinary shares for holders
PremiumThe Fly
Silexion Therapeutics files to sell 859,609 ordinary shares for holders
3M ago
SLXN
Silexion Therapeutics Implements 1-for-10 Reverse Share Split
PremiumCompany Announcements
Silexion Therapeutics Implements 1-for-10 Reverse Share Split
4M ago
8K
SLXN
Silexion Therapeutics Corp trading halted, news pending
PremiumThe FlySilexion Therapeutics Corp trading halted, news pending
4M ago
SLXN
Silexion Therapeutics announces 1-for-10 reverse share split
Premium
The Fly
Silexion Therapeutics announces 1-for-10 reverse share split
4M ago
SLXN
Silexion Therapeutics Announces Reverse Split to Maintain Listing
Premium
Company Announcements
Silexion Therapeutics Announces Reverse Split to Maintain Listing
4M ago
8K
SLXN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >